UNSPSC 51434943: Hydrochlorothiazide/metoprolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434943 Hydrochlorothiazide/metoprolol, a Commodity code, covers pharmaceutical supply and distribution for state and local emergency response, public health, and institutional care programs. State and local governments procure specific branded or generic pharmaceutical formulations—in this case combination antihypertensive agents—through sealed bids, RFPs, and cooperative purchasing alliances targeting emergency medical services, public health departments, correctional facilities, and allied institutional buyers. Issuing bodies include municipal fire and rescue departments (which operate EMS services), state health and human services agencies, and multistate cooperative purchasing organizations that aggregate demand across member jurisdictions. The work involves direct manufacturer or authorized-wholesaler pharmaceutical supply under contracts specifying NDC codes, packaging configurations, expiration-date minimums, delivery timelines, and compliance with FDA, cGMP, and DSCSA requirements.

Recent activity shows municipal and state purchasing across the South and Upper Midwest. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, with a $40,000 estimated contract value and a 5 percent SLBE bid discount available; the bid required sealed submission by April 8, 2026. The Texas Health and Human Services Commission issued an RFI in March 2026 to assess vendor capacity for direct-to-manufacturer pharmacy benefit programs as part of a broader Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), a two-year initial contract term, and 3 percent administrative fees on purchases. MMCAP's cooperative structure spans multiple states including Oregon, broadening the geographic reach beyond single-jurisdiction buys.